A Study of Effect of Different Biochemical Markers including Leptin and Spexin in Children Before and After Having Hypothalamus Surgery

Overview

About this study

The purpose of this study is to learn more about the changes in levels of Spexin, leptin and other biomarkers such as adiponectin and resting energy expenditure before and after hypothalamic surgery.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria 

Children with Hypothalamic Ovesity:

  • History of a tumor in the sellar/suprasellar region with hypothalamic involvement
  • Age 2-17 years
  • Stable hormone replacement therapy for more than 6 months (with levothyroxine, glucocorticoids and sex steroids)

Control Samples:

  • Patients with simple obesity who have previously participated in a clinical trial aimed at studying the effect of vitamin-D supplementation on insulin action
  • Age 12-18 years

Exclusion Criteria: 

  • Untreated pituitary dysfunction except for untreated growth hormone deficiency
  • Type 1 or 2 diabetes mellitus
  • Previous (within 6-months) or current use of weight loss medication
  • Previous (within 6-months) or current use of drugs associated with weight gain (e.g. steroids/anti-psychotics)
  • Previous bariatric surgery
  • Recent initiation (within 3-months) of anti-hypertensive or lipid medication
  • Obesity associated with genetic disorder (monogenetic obesity)

Control Samples:

  • Hepatic or Renal disorders.
  • Type 1 or Type 2 diabetes mellitus.
  • Ongoing use of insulin, metformin, or oral hypoglycemic medications.
  • Malabsorption disorders (celiac disease, cystic fibrosis, and inflammatory bowel disease.
  • Serum 25(OH) D > 100 ng/mL, and serum calcium > 10.8 mg/dL.
  • Use of glucocorticoids or anti-seizure medications in the preceding 6 months, ongoing multivitamin supplementation

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Aida Lteif, M.D.

Closed for enrollment

Contact information:

Aida Lteif M.D.

(608)392-9882

Lteif.Aida@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available